Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.

Machine translation Machine translation
类别 Primary study
期刊Journal of clinical gastroenterology
Year 2008
連結 Pubmed, DOI
背景：改性组织学活性指数（HAI）评分已被广泛使用，因为在大多数第三阶段枢轴治疗临床上慢性乙型肝炎的改进改性HAI试验额外的伯或仲结束点之后的抗病毒疗法通常被定义为2 - 点减少修改HAI得分。 目的：我们研究了2点的变化修改HAI得分的抗病毒治疗慢性乙型肝炎后是否有进展为肝并发症（失代偿性肝硬化或肝细胞癌）相关联。 方法：将80名患者在治疗结束后，治疗干扰素α与肝活检前和6〜12个月随访的中位数119.4个月。 结果：在分析时，11例（12.4％）有肝脏并发症。肝脏并发症较高的患者进行了2个百分点的增长中修改HAI评分在治疗结束[8月19日的例（42.1％）对3的70例（4.3％），P = 0.0002]，并有严重纤维化[6 19例（31.6％）与70例（7.1％）5，p = 0.010]。在Cox回归分析，2点增加改良HAI评分增加肝脏并发症（相对危险度5.564，P = 0.036）有关。 结论：2点增加改良HAI得分抗病毒治疗后，增加发展成肝癌的并发症有关。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: f0dfa7c0ac56f4b10bbc0acd52aff469759b0f4d
First added on: Mar 10, 2015
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use